Vaccination News Home Page                                            subscribe Vaccination NewsLetter

TSE Removal Claims for Plasma Derivative Labeling To Be Addressed By Cmte.

FDA is asking the Transmissible Spongiform Encephalopathies Advisory Committee at a Feb. 20 meeting whether the agency should consider labeling claims for the clearance of TSE agents in plasma derivatives, based upon specific demonstration of TSE removal during manufacturing.

Current plasma derivative labeling includes a warning that "because (this product) is made from human blood, it carries a risk of transmitting infectious agents, e.g. viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent."

FDA’s proposed draft labeling would add the statement: "It has been demonstrated that (the manufacturer’s) manufacturing process provides substantial clearance of agents similar to those causing CJD and variant CJD. Thus the theoretical risk of transmission of CJD or vCJD is considered extremely remote."

FDA noted that "the most feasible strategy for significantly reducing risk at this time is removal of potential TSE infectivity by manufacturing procedures." The agency added that "no single manufacturing step can be considered ‘generically’ effective in removing" such agents.

Clearance of TSE agents is also complicated by "uncertainties regarding the nature of this pathogen," FDA said. "The physico-chemical characteristics of TSE agents in human blood, if present there, remain unknown."

A science-based labeling claim of "specific TSE agent clearance might…provide an incentive for industry to study and to pursue reduction of TSE risk via manufacturing processes," FDA suggested.

Such an incentive is especially important because "validated and licensed blood screening tests for detecting donors incubating TSEs seem unlikely to be available in the near future."

To watch a live or archived webcast of this meeting, click the button below. To arrange for live videoconferencing or to order videotapes and CDs, email webcasthelp@elsevier.com
or call 800-332-1370 ext. 7210.
 

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.